JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Zai Lab Ltd ADR

Geschlossen

BrancheGesundheitswesen

22.8 4.64

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.67

Max

23.05

Schlüsselkennzahlen

By Trading Economics

Einkommen

-14M

-50M

Verkäufe

12M

128M

Gewinnspanne

-39.506

Angestellte

1,784

EBITDA

-17M

-48M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+61.2% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

642M

2.9B

Vorheriger Eröffnungskurs

18.16

Vorheriger Schlusskurs

22.8

Nachrichtenstimmung

By Acuity

34%

66%

124 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2026, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Group Rejects EQT's Revised Offer

24. Apr. 2026, 23:37 UTC

Akquisitionen, Fusionen, Übernahmen

Scoring the Cook Era -- Barrons.com

24. Apr. 2026, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:50 UTC

Market Talk
Wichtige Nachrichtenereignisse

Financial Services Roundup: Market Talk

24. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:09 UTC

Ergebnisse

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. Apr. 2026, 19:48 UTC

Market Talk
Wichtige Nachrichtenereignisse

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. Apr. 2026, 19:22 UTC

Ergebnisse

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. Apr. 2026, 19:06 UTC

Ergebnisse

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. Apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. Apr. 2026, 18:30 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. Apr. 2026, 18:28 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Rejects Revised EQT Offer

24. Apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. Apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. Apr. 2026, 17:42 UTC

Ergebnisse

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. Apr. 2026, 17:28 UTC

Ergebnisse

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24. Apr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24. Apr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24. Apr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24. Apr. 2026, 17:09 UTC

Market Talk
Ergebnisse

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24. Apr. 2026, 17:09 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 17:06 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24. Apr. 2026, 16:51 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24. Apr. 2026, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

24. Apr. 2026, 16:20 UTC

Market Talk
Wichtige Nachrichtenereignisse

Financial Services Roundup: Market Talk

24. Apr. 2026, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

24. Apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Zai Lab Ltd ADR Prognose

Kursziel

By TipRanks

61.2% Vorteil

12-Monats-Prognose

Durchschnitt 35.27 USD  61.2%

Hoch 47 USD

Tief 21.8 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zai Lab Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

28.13 / 31.12Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

124 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat